Multicentre phase II trial of capecitabine plus oxaliplatin (XELOX) in patients with advanced hepatocellular carcinoma: FFCD 03-03 trial

Evaluation of new drug combinations is needed to improve patients' prognosis in advanced hepatocellular carcinoma (HCC). The purpose of this study was to evaluate the safety and efficacy of the capecitabine–oxaliplatine combination (XELOX) in HCC patients. First-line chemotherapy with XELOX reg...

Descripción completa

Detalles Bibliográficos
Autores principales: Boige, V, Raoul, J-L, Pignon, J-P, Bouché, O, Blanc, J-F, Dahan, L, Jouve, J-L, Dupouy, N, Ducreux, M
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2007
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360397/
https://www.ncbi.nlm.nih.gov/pubmed/17876335
http://dx.doi.org/10.1038/sj.bjc.6603956

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360397/
https://www.ncbi.nlm.nih.gov/pubmed/17876335
http://dx.doi.org/10.1038/sj.bjc.6603956

Ejemplares similares